Tag: Heart Failure
AHA: Variation Seen in Rates of SGLT2i Rx for Heart Failure, LVEF >40 Percent
Prescription rates increased from 2021 to 2023, but high variance seen between hospitals in the rate of prescriptions
Heart Failure With Preserved Ejection Fraction Underdiagnosed
Findings seen in patients with severe secondary tricuspid regurgitation of undefined etiology
AHA: Tirzepatide Beneficial for Heart Failure With Preserved EF, Obesity
Lower risk for composite of death from cardiovascular causes or worsening heart failure seen with tirzepatide versus placebo
Palliative Care Use Low in Patients With Heart Failure
Authors recommend patient and physician education and changes to practice guidelines and payment to overcome barriers to palliative care use
Substantial Mortality Benefits Expected From Optimal Medication Use for HFrEF
1,188,277 deaths could potentially be prevented over 12 months with optimal implementation of quadruple guideline-directed medical therapy
About 6.7 Million Americans Older Than 20 Years Have Heart Failure
Prevalence expected to continue increasing and reach 11.4 million in 2050; lifetime risk for heart failure up to 24 percent
Event-Free Survival Extended With Long-Term Finerenone in Heart Failure
Long-term finerenone extends event-free survival up to three years for heart failure with mildly reduced or preserved ejection fraction
Endovascular Therapy Improves Left Ventricular Diastolic Function in HFpEF
Improvement seen in aortic function, with significantly reduced augmentation index and pulse wave velocity and increased compliance
Empagliflozin Confers Kidney-Protective Benefits After Acute MI
Reduced risk seen for total hospitalizations for heart failure, total adverse events of heart failure or all-cause mortality
Semaglutide Reduces Risk for MACE in Patients With Obesity and Heart Failure
MACE, heart failure composite end point, cardiovascular death, and all-cause death all improved with semaglutide for patients with versus without heart failure